Apparatuses and methods are disclosed for gathering biological samples from medium to large terrestrial mammals, such as gathering a blood sample from an animal. A remote blood collection apparatus, or dart, includes a fluid collection reservoir maintaining a vacuum, and one or more sharpened tubular ends, which may be one or more needles. In response to the apparatus being driven into an animal, a continuous passage is created from the fluid collection reservoir through the one or more sharpened tubular ends. The apparatus is configured to extract, using the vacuum in the fluid collection reservoir and from the animal, fluid into the fluid collection reservoir from the animal. The apparatus provides advantages over known blood collection techniques, as well as known biopsy needles that take a sample of core flesh along with blood and may result in inaccurate sample analysis.
A61D 99/00 - Subject matter not provided for in other groups of this subclass
F42B 12/54 - Projectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for dispensing materialsProjectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for producing chemical or physical reactionProjectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for signalling for dispensing gases, vapours, powders or chemically-reactive substances by implantation, e.g. hypodermic projectiles
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Systems and methods are provided for performing ultrasound imaging using directional information obtained by beamforming signals received from electrode pairs of one or more multiaxial ultrasound transducers. Multiaxial ultrasound transducers include an electro- acoustically active material or substrate having disposed on, or contacted with, at least two pairs of electrodes arranged along different axes. Signals received from the multiple electrode pairs may be beamformed to determine direction of arrival information associated with incident ultrasound energy, and the direction of arrival information may be employed, optionally with time-of-flight information, for active or passive imaging applications. An ultrasound computed tomography system may be adapted to include multiaxial ultrasound transducers, from which receive signals may be directionally beamformed to determine a direction of arrival associated with each receive event during ultrasound computed tomography data acquisition. The direction of arrival information may be employed, optionally in conjunction with time-of-flight information, when performing image reconstruction.
G01N 29/06 - Visualisation of the interior, e.g. acoustic microscopy
G01N 29/14 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object using acoustic emission techniques
G01S 3/808 - Systems for determining direction or deviation from predetermined direction using transducers spaced apart and measuring phase or time difference between signals therefrom, i.e. path-difference systems
4.
ELECTRODES USEFUL FOR MEMBRANE-FREE ELECTRODE ASSEMBLIES, MEMBRANE-FREE ELECTRODE ASSEMBLIES, METHODS, AND USES THEREOF
Electrodes useful for membrane-free electrode assemblies, membrane-free electrode assemblies, methods of making, and uses thereof. The electrodes comprise a catalyst layer; and a solid polymer electrolyte layer for ion-conduction deposited on the catalyst layer. The solid polymer electrolyte layer is deposited on a catalyst layer as an ionomer resin solution and forms an ion conducting layer thereby eliminating the need for a stand-alone membrane that is introduced as a separate component into electrode assemblies.
C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
A novel strategy aims to replicate the complex microenvironment of the intestine by cultivating intestinal cells within bioinspired 3D interfaces that mimic the intricate villus-crypt architecture of the intestine, including its 3D arrangement, morphological components, and matrix gradients. This design demonstrates superior efficacy in mimicking intestinal tissue compared to existing approaches and leads to complete proliferation and differentiation of cultured intestinal cells and tissues in significantly shorter timeframes than typically required by other bioengineered materials and systems for similar outcomes.
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07H 5/02 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
7.
EFFECTIVE ISOLATION AND USE OF MYCOBACTERIOPHAGES WITH ABILITY TO LYSE MYCOBACTERIUM AVIAN SUBSP. PARATUBERCULOSIS
Johne's disease (JD), a chronic infectious enteritis of ruminants causes major economic losses in the dairy industry globally. This enteritis is caused by Mycobacterium avium subsp. paratuberculosis (MAP). Described herein are mycobacteriophage and methods of use thereof.
C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
A hydrogen storage and/or delivery system comprises a hydrogen storing emulsion formed from a perfluorocarbon (PFC) and a surfactant present in an aqueous medium. The hydrogen storing emulsion releasably retains hydrogen gas and may be in a hydrogen containing emulsion state or a hydrogen absorbable emulsion state. The emulsion may be supplied in a vessel configured to receive and provide hydrogen gas, thereby comprising a device for storing and providing hydrogen gas. The hydrogen containing emulsion may be configured to release the hydrogen gas upon sonication.
Highly flexible, lubricant-infused silane-crosslinked polyvinyl alcohol (PVA) films as well as methods of making and using such films. Lubricant-infused properties are introduced throughout the entire volume of the film. An organosilane crosslinking agent, such as an alkyl silane crosslinking agent, and more specifically propyl trichlorosilane (nPTCS) is used to generate a crosslinked PVA film on a substate or as a free-standing film or membrane. The crosslinked film or membrane is infused with a compatible lubricant, such as silicone oil, to produce a lubricant-infused crosslinked PVA film. Stable lubricant-infused films are provided that exhibit significantly enhanced antibacterial and antithrombotic properties compared to control PVA film samples. Such films can be formed on any surface that comes in contact with a biological fluid to provide protection from fouling by that biological fluid. Articles provided with such films include, for example, fluid conduits, seals, optical articles and medical devices inserted and retained in the body.
The present disclosure describes systems and methods for producing graphene sheets and a graphene, additive-free aqueous-based ink for direct ink writing (DIW) at room temperature, which may be used, for example, to 3D-print functional aerogels for electronics and electromagnetic interference (EMI) shields. The graphene sheets may comprise a thickness from about 1 nm to about 40 nm; and/or a G-band from about 1585 cm-1to about 1592.5 cm-1 as measured by Raman spectroscopy; and/or interlayer spacing of about 6.51 Å to 6.61 Å as measured by X-ray diffraction; and/or an atomic ratio of carbon to oxygen of about 3.56 to about 5.44 as measured by X-ray photoelectron spectroscopy. The graphene ink may comprise the graphene sheets and an aqueous solution. A kit comprising graphene sheets and a container is also provided.
The present invention is directed to a pharmaceutical composition and method for treating a subj ect diagnosed amyotrophic lateral sclerosis (ALS) with a pharmaceutical composition containing dissolved or dispersed therein a SOD1 and/or TDP-43 aggregation- inhibiting amount of a rose bengal (RB) compound that is a pharmaceutically acceptable salt of RB, RB lactone, a RB amide, an aromatic RB derivative, wherein the aromatic derivative is an ester or amide formed from an alcohol or monosubstituted amine having a 5 - or 6 -membered aromatic ring, or a 5, 6 - or 6, 6 - fused aromatic ring system that contains 0, 1, or 2 hetero ring atoms that are independently nitrogen, oxygen or sulfur. This treatment method is typically repeated a plurality of times or until the subj ect no longer needs it.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention is directed to a pharmaceutical composition and method for treating a subject diagnosed amyotrophic lateral sclerosis (ALS) with a pharmaceutical composition containing dissolved or dispersed therein a SOD1 and/or TDP-43 aggregation-inhibiting amount of a rose bengal (RB) compound that is a pharmaceutically acceptable salt of RB, RB lactone, a RB amide, an aromatic RB derivative, wherein the aromatic derivative is an ester or amide formed from an alcohol or monosubstituted amine having a 5- or 6-membered aromatic ring, or a 5,6- or 6,6-fused aromatic ring system that contains 0, 1, or 2 hetero ring atoms that are independently nitrogen, oxygen or sulfur. This treatment method is typically repeated a plurality of times or until the subject no longer needs it.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
13.
USES OF HALOGENATED XANTHENES IN ONCOLOGY AND VIROLOGY
A method for treating a viral infection of a mammalian subject that comprises administering a virus- inhibiting amount of a halogenated xanthene, a pharmaceutically acceptable salt, an alkyl ester or amide or aromatic ester or amide derivative thereof as disclosed within, to that mammalian subject. A method of inducing a type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene as discussed above, and an immunogen to which that response is to be enhanced.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
Methods, systems and devices are provided for utilizing user movement data obtained from one or more wearable sensors during physical activity to compare individualized changes overtime, for example typical versus atypical movement patterns, with subgroup analyses for assessing changes between other users in order to develop an assessment of movement for, for example, tracking injury risk, performance, and/or rehabilitation. The movement information may comprise multi-sensor, high dimensional datasets. Techniques are provided for integrating human movement data from one or more wearable sensor with one or more additional data sources to define an individualized movement profile of a user's movements. The user or another individual may be notified when the user's movements deviate from this individualized movement profile.
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
15.
SYSTEM AND METHOD FOR CONTROL OF AUTONOMIC FUNCTION
Ecole Polytechnique Federale de Lausanne (EPFL) (Switzerland)
UTI LIMITED PARTNERSHIP (Canada)
Inventor
Courtine, Gregoire
Phillips, Aaron
Squair, Jordan
Abstract
A system for neuromodulation and/or neurostimulation, for the treatment of a mammal, at least comprising:
at least one control unit configured and arranged to provide stimulation data;
at least one stimulation unit configured and arranged to provide a stimulation pulse;
at least one real-time monitoring unit;
at least one signal-processing unit;
A system for neuromodulation and/or neurostimulation, for the treatment of a mammal, at least comprising:
at least one control unit configured and arranged to provide stimulation data;
at least one stimulation unit configured and arranged to provide a stimulation pulse;
at least one real-time monitoring unit;
at least one signal-processing unit;
wherein the system is configured and arranged for control of blood pressure, wherein the stimulation unit is constructed to comprise a lead, and wherein the lead is capable and configured to provide stimulation to the spinal cord at level T9-L1.
Methods and systems of changing ion concentrations in a water, involving extracting and providing ions from and to water masses or aliquots, where extracting and providing said ions may motivate partitioning of CO2 into the water.
Disclosed is a compound of formula I, or a salt thereof, where ●, ο, R1, R2 and ---------- are as defined in the specification Also, disclosed is a process for the preparation of the compound of formula (I), or a salt thereof. The compound of formula I, or a salt thereof, can be used for the capture, or capture and release of carbon dioxide. In addition, the compound of formula I, or a salt thereof, can be used for the capture and reduction of carbon dioxide to formic acid, or a salt thereof.
B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (Switzerland)
UTI LIMITED PARTNERSHIP (Canada)
Inventor
Courtine, Grègoire
Phillips, Aaron
Squair, Jordan
Abstract
The invention provides a neuromodulation/neurostimulation system (10) for stimulating sympathetic circuitry responsible for blood pressure control in a mammal with autonomic dysreflexia, said system (10) comprising: at least one control unit (12) configured and arranged to provide stimulation data, and at least one stimulation unit (14), operatively connected to the at least one control unit (12), said at least one stimulation unit (14) being configured and arranged to provide electrical stimulation to the spinal cord of said mammal, preferably at thoracic level, more preferably around spinal cord level T10-T12. The at least one stimulation unit (14) includes an implantable lead (18). The neuromodulation/neurostimulation system is configured and arranged to provide neuromodulation to said mammal to activate the sympathetic circuitry responsible for blood pressure control that mitigates autonomic dysreflexia.
An electrochemical sensor for the detection of a selected analyte and methods of detecting the selected analyte. The sensor comprises an active layer containing a sensing material dispersed in a semiconducting and/or conducting polymer. The conductance of the active layer is responsive to the presence/amount of selected analyte in the active layer. The sensing material comprises a pi-conjugated moiety and at least one chemical functional group bonded to the pi- conjugated moiety, interaction of the sensing material with the selected analyte induces charge transfer into the active layer to change the conductance of the active layer. Example selected analytes are volatile bases, particularly ammonia, volatile amines, diamine or polyamines. Example sensing material is the N-Annulated perylene diamine NPDI-NH.
The present application discloses methods of carbon capture and storage using a carbon storage vector formed by providing a feedstock comprising a reactive saccharide, an amino-functionalized component and/or an alkenyl-functionalized component; thermally treating the feedstock; and optionally, when the feedstock comprises an alkenyl-functionalized component, thermally treating the feedstock in the presence of elemental sulfur to vulcanize the alkenyl-functionalized component.
Disclosed is a carborane of formula I, or a salt thereof, wherein ●, ο, E, J and Q are as disclosed herein Also disclosed is a process for synthesis of the carborane of formula I, or a salt thereof, an apparatus for capturing a metal ion, a method for manufacturing the apparatus for capturing a metal ion, and a method of capturing a metal ion. The carborane of formula I, or salt thereof, can be used for capturing a metal ion.
C07F 9/6571 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
C07F 17/02 - Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
C25C 3/02 - Electrolytic production, recovery or refining of metals by electrolysis of melts of alkali or alkaline earth metals
Disclosed is a carborane of formula I, or a salt thereof, wherein ●, ο, E, J and Q are as disclosed herein Also disclosed is a process for synthesis of the carborane of formula I, or a salt thereof, an apparatus for capturing a metal ion, a method for manufacturing the apparatus for capturing a metal ion, and a method of capturing a metal ion. The carborane of formula I, or salt thereof, can be used for capturing a metal ion.
C07F 9/6571 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
C07F 17/02 - Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
C25C 3/02 - Electrolytic production, recovery or refining of metals by electrolysis of melts of alkali or alkaline earth metals
24.
SYNERGISTIC CONVERSION OF BITUMEN AND BIOMASS INTO HIGH PERFORMANCE CARBON MATERIALS
A method of forming activated carbon is provided wherein bitumen, biomass, and an activating agent are combined to form a mixture and then the mixture is heated under an inert atmosphere to form activated carbon. Activated carbon materials and uses thereof are also provided.
C01B 32/318 - Preparation characterised by the starting materials
B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
System and method for geo-positioning using a plurality of chained reference stations. A user station receives station-generated correction information-that is, SSR corrections that generated by a single station and unique to that reference station and positioning information from the specific reference station. A user-positioning module of the user station processes the received positioning information, as well as the reference station's station-specific corrections, to determine the user station's location. In some embodiments, the user station receives positioning and unique correction information from multiple reference stations. The user-positioning module then fuses the received information to determine the user station's location. Additional reference stations can be added to the reference station network by propagation. The reference station's position is known to a predetermined degree of precision.
G01S 19/07 - Cooperating elementsInteraction or communication between different cooperating elements or between cooperating elements and receivers providing data for correcting measured positioning data, e.g. DGPS [differential GPS] or ionosphere corrections
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Permselective gas diffusion electrodes (PGDE) for electrocatalytic reduction of CO2 and/or CO·CO2- or CO-selective mixed matrix membranes (MMM) to facilitate enhanced permeance of CO2 or CO, respectively, into the PGDE facilitate electrocatalytic reduction of CO2 or CO. Permselective MMM include a filler of intrinsic nanopores (FINs) which can be a metal organic framework (MOF), activated carbon (AC), zeolite or covalent organic framework (COF)) that exhibits selective adsorption of CO2 or CO. An alkaline flow cell or membrane electrode assembly for CO2 or CO reduction which comprises a permselective PGDE is also provided. Further provided are methods of separating CO2 from CO2-containing gases for electrochemical reduction of CO2. Also provided are methods of separating CO from CO-containing gases for electrochemical reduction of CO. Also provided are methods for electrocatalytic reduction of CO2 and/or CO to produce C2+ products.
B01D 53/32 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
Provided are computer-implemented systems and methods for generating a health outcome prediction, including: receiving user data, the user data comprising passively collected data by a passive data collection monitoring device associated with the user; self-reported health metrics associated with the user; receiving clinical health outcome data, the clinical health outcome data comprising at least one health outcome based on clinical data; extracting a plurality of variables from the user data; providing the plurality of variables and the clinical health outcome data as inputs to at least one machine learning model to identify at least one selected variable from the plurality of variables, having an associated predictive value to the clinical health outcome data; generating based on the at least one selected variable, an individualized prediction algorithm for generating the health outcome prediction; applying the individualized prediction algorithm to the user data to generate the health outcome prediction.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
30.
PROCESS FOR PREPARING METAL-ORGANIC FRAMEWORKS, METAL-ORGANIC FRAMEWORKS, AND USES THEREOF
B01J 31/12 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing organo-metallic compounds or metal hydrides
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
31.
PROCESS FOR PREPARING METAL-ORGANIC FRAMEWORKS, METAL-ORGANIC FRAMEWORKS, AND USES THEREOF
A process for preparing a mixed-metal metal-organic framework. The process comprises providing a hydrogen bonded metal organic framework (HM1OF); soaking the hydrogen bonded metal organic framework (HM1OF) in a metal (M2)-comprising solution; and forming a mixed-metal MOF (M1OF-M2), where M1 and M2 are different metals.
B01J 31/12 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing organo-metallic compounds or metal hydrides
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A Janus particle, comprising a particle core, the particle core comprising at least a first surface functionalized with a functional group and a second surface functionalized with a metal particle.
B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B01J 20/02 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material
B01J 20/30 - Processes for preparing, regenerating or reactivating
An apparatus and methods are provided that operate to stabilize blood flow at the site of an injury in a patient, particularly in tissues of the central nervous system. Such an apparatus and methods may mitigate the severity of an injury by optimizing blood flow and reducing secondary damage, leading to improved neurological recovery. A closed-loop system may control one or more parameters at the site of injury by regulating circulating carbon dioxide levels or carbon dioxide and oxygen and/or pH. An example embodiment includes a controller that controls a gas mixer to vary the CO2 concentration in a gas supplied for breathing by a patient in response to an output signal from a sensor that monitors one or more desired outcomes. Example applications of the present technology include treating spinal cord injury, traumatic brain injury, and cardiac condition or event.
A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
C07D 307/06 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
C09K 8/58 - Compositions for enhanced recovery methods for obtaining hydrocarbons, i.e. for improving the mobility of the oil, e.g. displacing fluids
C10G 1/04 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal by extraction
The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A method of hydrocarbon recovery, involving converting a lignocellulosic biomass into a bio-oil solvent, the bio-oil solvent being at least partially deoxygenated; contacting the bio-oil solvent with a mixture comprising a hydrocarbon; and extracting the hydrocarbon into the solvent. The extracted hydrocarbon may be bitumen.
C10G 1/04 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal by extraction
A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
C07D 307/06 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
C09K 8/58 - Compositions for enhanced recovery methods for obtaining hydrocarbons, i.e. for improving the mobility of the oil, e.g. displacing fluids
C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
Herein provided are methods of forming stable nanocrystalline high-entropy alloys (HEAs). The method may include: processing a mixture of at least four or more principal elements in equiatomic or near-equiatomic ratios to form a single-phase solid solution HEA as a solvent; adding a solute element to the solvent, the solute element having a different crystal structure, an atomic size mismatch of at least 15%, and a higher melting point than the solvent; processing the solvent and the solute element until a single-phase solid solution HEA is formed; and annealing the single-phase solid solution HEA at 0.46 to 0.67 of the melting temperature of the HEA to form the stable grain-boundary-decorated nanocrystalline HEA. The nanocrystalline HEAs may be stabilized against grain growth and phase decomposition, including short and long- range orderings, at high homologous temperatures.
C02F 1/30 - Treatment of water, waste water, or sewage by irradiation
C02F 1/50 - Treatment of water, waste water, or sewage by addition or application of a germicide or by oligodynamic treatment
C04B 35/453 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on zinc, tin or bismuth oxides or solid solutions thereof with other oxides, e.g. zincates, stannates or bismuthates
C04B 35/58 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on borides, nitrides or silicides
Herein disclosed is a method of forming a nanocomposite material that includes: dispersing graphitic carbon nitride (GCN) nanosheets in a solvent by ultrasonication to form a GCN nanosheet dispersion; adding zinc oxide-copper (ZnO-Cu) nanoparticles to the GCN nanosheet dispersion to form a GCN/ZnO-Cu mixture; co-exfoliating the GCN/ZnO-Cu mixture by first ultrasonicating and then calcinating the dried GCN/ZnO-Cu sample to form the nanocomposite material. Also provided are articles comprising the GCN/ZnO-Cu nanocomposite material and methods of coating articles in the nanocomposite material. Such articles may be used in disinfection.
A01N 25/34 - Shaped forms, e.g. sheets, not provided for in any other group of this main group
A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
C01B 21/082 - Compounds containing nitrogen and non-metals
C02F 1/30 - Treatment of water, waste water, or sewage by irradiation
C02F 1/50 - Treatment of water, waste water, or sewage by addition or application of a germicide or by oligodynamic treatment
C04B 35/58 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on borides, nitrides or silicides
C04B 35/453 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on zinc, tin or bismuth oxides or solid solutions thereof with other oxides, e.g. zincates, stannates or bismuthates
C08J 7/06 - Coating with compositions not containing macromolecular substances
An electroseparator is provided comprising an injection portion having a first inlet configured to receive a sample solution at a sample solution flow rate, the sample solution comprising at least one target charged particle; a separation portion fluidly connected to the injection portion; a collection portion fluidly connected to the separation portion the collection portion comprising a first outlet configured to dispense the at least one target particle and a second outlet configured to dispense a carrier solution; an anode end; a cathode end opposite the anode end; the cathode end electrically coupled to the anode end for delivering a constant electric field across the separation portion. Also provided is a method of separating charged particles comprising providing a sample solution having a flow rate, comprising at least one target charged particle and at least one non-target charged particle, and applying a constant electric field across the sample solution.
An organo-metallic complex, comprising at least one ligand coordinating an early transition metal, the ligand comprising a cyclic imidedioxime, and the early transition metal comprising vanadium; method of synthesizing cyclic imidedioxime ligands; methods of extracting vanadium; and uses of the same.
C07F 9/00 - Compounds containing elements of Groups 5 or 15 of the Periodic Table
B01J 31/36 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of vanadium, niobium or tantalum
C07B 41/00 - Formation or introduction of functional groups containing oxygen
C07D 211/84 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
C07D 221/14 - Aza-phenalenes, e.g. 1,8-naphthalimide
B01J 31/36 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of vanadium, niobium or tantalum
C07B 41/00 - Formation or introduction of functional groups containing oxygen
C07D 211/84 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
C07D 221/14 - Aza-phenalenes, e.g. 1,8-naphthalimide
C07F 9/00 - Compounds containing elements of Groups 5 or 15 of the Periodic Table
Described herein are heterodimers containing at least one first polypeptide and at least one second polypeptide, wherein the first polypeptide and the second polypeptide meet at an interface, wherein the interface of the first polypeptide contains an engineered protuberance which is positionable in an engineered cavity in the interface of the second polypeptide; and (i) the first polypeptide contains an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; or (ii) the first polypeptide contains an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
48.
SYSTEMS AND METHODS FOR DETECTING OCULAR LESIONS IN FUNDUS IMAGES
Methods and systems are described for detecting ocular lesions indicative of an ocular pathology. The methods and systems involve obtaining a fundus image of an eye of a patient, preprocessing the fundus image to obtain a processed fundus image applying a detection model to the processed fundus image to identify whether a lesion is present in the fundus image providing an output based on an output result of the detection model. The detection model is configured for detecting ocular lesions in fundus images and the output is related to a lesion being present in the fundus image.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
49.
NEURAL SPATIOTEMPORAL DYNAMIC BARCODING AND METHODS OF ASSESSING CHANGES IN CORTICAL DYNAMICS USING THE SAME
A61B 5/16 - Devices for psychotechnicsTesting reaction times
G06K 19/06 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
G06T 7/30 - Determination of transform parameters for the alignment of images, i.e. image registration
G16H 30/00 - ICT specially adapted for the handling or processing of medical images
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present disclosure relates generally to the treatment of Fragile X Syndrome using a recombinant fusion polypeptide comprising or consisting of a cell penetrating polypeptide, such as HIS or tat, and a Fragile X Mental Retardation protein (FMRP (298)).
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A biosensor wearable by a user is provided comprising a sensor configured to be retained by a casing, the sensor having a contact surface for contacting the user, the contact surface comprising a concatenated aptamer, the concatenated aptamer configured to bind to a target biomolecule for generating a signal indicating a change in electrical resistance corresponding to a concentration of the target biomolecule.
The present disclosure provides a method of determining a likelihood of a favorable or unfavorable outcome, such as death or a Glasgow Outcome Scale Extended (GOSE) score≤4, in a subject having severe traumatic brain injury (sTBI). The method involves quantitative assessment of multiple metabolites shortly after the injury, such as on day 1 and/or day 4 for changes indicative of outcome. Quantitative mass spectrometry (MS) or proton (1H) nuclear magnetic resonance spectroscopy (NMR) may be used to assess multiple metabolites within a single blood sample for comparison with a control.
In one aspect, there is a provided a method of treating pain in a subject in need thereof comprising administering to the subject an anaplastic lymphoma kinase (ALK) inhibitor. In one aspect, there is a provided a method of treating pain in a subject in need thereof comprising administering to the subject an ALKAL2 inhibitor.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
54.
PEA PLANTS WITH REDUCED SAPONIN CONTENT AND RELATED COMPOSITIONS AND METHODS
System and method for correcting GNSS NLOS error using ray-tracing. A processor is in communication with a receiver configured to receive a signal from at least one signal source. A ray-tracing module of the processor performs ray-tracing on a plurality of simulated testing rays that pass through a low-resolution pixel shader image. Then, results of the first ray-tracing process are clustered based on reflection surfaces combination encountered and mirror-based ray-tracing is performed on the clustered results. A best result of the mirror-based ray-tracing process (i.e., a result having the highest signal power) is selected, corresponding to a most likely path between said receiver and the signal source, and is useful for correcting errors in signals received by the signal.
Embodiments of the present invention are directed to a method of synthesizing a nanoparticle, e.g., asphaltene quantum dots ("AQD") and/or asphaltene carbon dots ("ACD"), the method comprising: contacting a source of asphaltene with an organic solvent to form an asphaltene and organic solvent mixture; removing; contacting the asphaltene and organic solvent mixture with an acid to form an acidic mixture; heating the acidic mixture to form an unpurified AQD and/or ACD; removing the acid; and adjusting the pH to form the AQD and/or ACD.
Systems and methods for determining a user's absolute acceleration/deceleration on an Earth based reference frame. Signals from multiple satellites are received and the Doppler rate for each satellite is extracted using baseband signal processing. Then, using each satellite's ephemeris, the acceleration/deceleration and Earth frame position of each satellite is determined. The user's absolute position is then used, along with each satellite's position to calculate direction cosine vector projections for each satellite. The user's absolute acceleration/deceleration is then calculated using the various direction cosine vector projections, the various satellite acceleration/deceleration values, and each satellite's Doppler rates. The resulting absolute acceleration/deceleration can then be used for more accurate navigation solutions.
An MOF film comprising an MOF and an organic scaffold. The MOF is attached to the organic scaffold by hydrogen bonds. The MOF film may be a PCMOF and/or HKUST and may have proton conductive properties. The MOF film may comprise a coordinated metal. The organic scaffold may comprise cellulose material. The MOF film may be free standing without physical support from another material or structure, may be formed into shapes, and may be bent or folded. The MOF film may comprise an MOF and an organic scaffold at different weight ratios.
Multilayer organic electronic devices having an electron transport layer (ETL). The ETL is a film comprising an N-annulated perylene diimide (NPDI) compound having at least one pyrrole N—H bond and at least 1 equivalent of Cs2CO3 with respect to the NPDI compound and the number of pyrrolic N—H bonds in the NPDI compound. The ETL is positioned between the photoactive layer and the top electrode (cathode). Multilayer devices including the ETL are fabricated employing immiscible solvent methods. A method for making the ETL layers is provided which employs an ink formulation in which the NPDI compound is solubilized in a selected polar solvent by addition of at least one equivalent of Cs2CO3 respect to the NPDI compound. Exemplary polar solvents include ethanol, 1-propanol, ethyl acetate and mixtures thereof.
H10K 30/85 - Layers having high electron mobility, e.g. electron-transporting layers or hole-blocking layers
H10K 30/86 - Layers having high hole mobility, e.g. hole-transporting layers or electron-blocking layers
H10K 71/13 - Deposition of organic active material using liquid deposition, e.g. spin coating using printing techniques, e.g. ink-jet printing or screen printing
H10K 85/60 - Organic compounds having low molecular weight
H10K 102/20 - Metallic electrodes, e.g. using a stack of layers
62.
SORBENTS AND METHODS FOR CARBON CAPTURE VIA CALCIUM LOOPING
The present disclosure provides CO2 sorbent materials and methods of producing the same. The method includes: (a) combining calcium, at least one metal, and a fuel in a solvent to form a solution; (b) heating the solution formed in (a) to evaporate the solvent and form a combustion mixture; (c) heating the combustion mixture formed in (b) to combustion, to form a combusted material; and (d) calcinating the combusted material formed in (c) to form the CO2 sorbent. The CO2 sorbent may be used for capturing CO2, such as in a calcium looping process.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
63.
Multi-metal electrocatalytic system for methane oxidation
Methods and cells are provided for electrochemically oxidizing methane to formate, in which methane supplied to an alkaline aqueous anolyte medium comprising hydroperoxyl anions is brought into contact with an oxidation catalyst anode. The oxidation catalyst may include CuFe oxide catalytic centres supported on a nickel substrate. An anodic current supplied to the oxidation catalyst in the anolyte medium electrolytically oxidizes methane to formate.
C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
64.
MICRONEEDLE AND ARRAY AND METHOD OF FABRICATING SAME
A method of fabricating a microneedle is disclosed, including: applying a force to a conductive wire to create a friction weld between the wire and a substrate; extruding the wire and interrupting the wire bonding process; and applying a wire weakening process at a desired microneedle length to cause the wire to break at the desired microneedle length. A microneedle array includes a substrate and a plurality of solid microneedles provided on the substrate. Adjacent microneedles may have different heights and different diameters. The substrate defines a plurality of microfluidic channels each having a channel outlet. the channel outlets provided adjacent the bases of the plurality of solid microneedles to enable drug delivery. The method and array overcome issues with needle stick injuries and needle phobia, and can be used without direct medical supervision, thus reducing healthcare expenditure.
A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the Type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene, and an immunogen to which that response is to be enhanced. A mammalian HX compound-adjuvanted vaccine composition that contains an immunogen present in a vaccine-effective amount along with an adjuvant-effective amount of a halogenated xanthene (HX) compound and one or more excipients present at about 0.001% by weight to 10% by weight of the vaccine composition dissolved or dispersed in a pharmaceutically acceptable diluent.
The present application relates to the use of hydroxyphenyl propanoate compounds of Formula (I), (II), (III), (IV) or (V), or pharmaceutically acceptable salts, solvates and/or ester prodrugs thereof, to increase anti-tumour immunity, to compositions comprising them, and their use, for example, in cancer immunotherapy. More particularly, the present application relates to compounds useful in the treatment of diseases, disorders, or conditions treatable by increasing anti-tumour immunity in a cell, such as cancer.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
C07C 59/90 - Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
C07C 229/42 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
67.
HYDROXYPHENYL PROPANOATE COMPOUNDS FOR TUMOUR IMMUNOTHERAPY, COMPOSITIONS AND USES THEREOF
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
C07C 59/90 - Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
C07C 229/42 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
68.
CHROMIUM PHOSPHONATE METAL-ORGANIC FRAMEWORKS, PROCESS FOR PREPARING THE SAME AND USES THEREOF
The present application relates to metal-organic frameworks (MOFs). More specifically, the present application relates to process for their preparation and uses thereof. The present application includes a process for preparing a chromium (III) phosphonate metal-organic framework (MOF) comprising: a) dehydrating a hydrogen-bonded metal-organic framework (HMOF) comprising chromium (III) hydrogen bonded to one or more organic polyphosphonate molecule by heating the HMOF at a controlled rate; b) cooling the dehydrated HMOF from a) to provide the MOF.
C07F 11/00 - Compounds containing elements of Groups 6 or 16 of the Periodic Table
B01D 15/08 - Selective adsorption, e.g. chromatography
B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
B01J 20/30 - Processes for preparing, regenerating or reactivating
This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of TR1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
71.
SNAPSHOT GNSS RECEIVER AND METHOD USING SUPER-LONG COHERENT INTEGRATION AND FRACTIONAL FOURIER TRANSFORM
Snapshot receiver that comprises a correlator module for correlating incoming GNSS signals and a transform module that transforms resulting correlated outputs using a Fractional Fourier Transform (FrFT) process, to thereby compensate for weak and dynamic signals. The output of the transform module is an estimated Doppler rate with high accuracy. The estimated Doppler rate is passed to a super-resolution-measurement (SRM) module, which outputs error values of the estimated Doppler rate and a pseudorange (measured distance-to-satellite) via a phase dead reckoning (DR) calculation for the snapshot receiver. The pseudorange and error values are passed to a navigator module that determines position information based on those inputs. In some embodiments, the SRM module comprises a maximum likelihood estimator (MLE).
G01S 19/24 - Acquisition or tracking of signals transmitted by the system
G01S 19/29 - Acquisition or tracking of signals transmitted by the system carrier related
G01S 19/30 - Acquisition or tracking of signals transmitted by the system code related
G01S 19/37 - Hardware or software details of the signal processing chain
G01S 19/39 - Determining a navigation solution using signals transmitted by a satellite radio beacon positioning system the satellite radio beacon positioning system transmitting time-stamped messages, e.g. GPS [Global Positioning System], GLONASS [Global Orbiting Navigation Satellite System] or GALILEO
A61B 5/153 - Devices for taking samples of blood specially adapted for taking samples of venous or arterial blood, e.g. by syringes
A61D 99/00 - Subject matter not provided for in other groups of this subclass
F42B 12/54 - Projectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for dispensing materialsProjectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for producing chemical or physical reactionProjectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for signalling for dispensing gases, vapours, powders or chemically-reactive substances by implantation, e.g. hypodermic projectiles
Apparatuses and methods are disclosed for gathering biological samples from medium to large terrestrial mammals, such as gathering a blood sample from an animal. A remote blood collection apparatus, or dart, includes a fluid collection reservoir maintaining a vacuum, and one or more sharpened tubular ends, which may be one or more needles. In response to the apparatus being driven into an animal, a continuous passage is created from the fluid collection reservoir through the one or more sharpened tubular ends. The apparatus is configured to extract, using the vacuum in the fluid collection reservoir and from the animal, fluid into the fluid collection reservoir from the animal. The apparatus provides advantages over known blood collection techniques, as well as known biopsy needles that take a sample of core flesh along with blood and may result in inaccurate sample analysis.
A61B 5/153 - Devices for taking samples of blood specially adapted for taking samples of venous or arterial blood, e.g. by syringes
F42B 12/54 - Projectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for dispensing materialsProjectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for producing chemical or physical reactionProjectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for signalling for dispensing gases, vapours, powders or chemically-reactive substances by implantation, e.g. hypodermic projectiles
74.
DETECTING A DINUCLEOTIDE SEQUENCE IN A TARGET POLYNUCLEOTIDE
The present disclosure relates to improvements in the Dinucleotide signaTurE CapTure (DTECT) method. The improved detection of a dinucleotide sequence in a target polynucleotide generally involves the steps of Acu1 digestion, heat inactivation and ligation to unique adaptors containing overhangs of two bases complementary to the dinucleotide signature.
A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure is directed to compounds that may selectively inhibit Death Associated Protein Kinases (DAPKs) as well as PIM kinases. The compounds can be used in methods of treating various disorders, including cancers.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Disclosed herein are hydrogel precursor solutions, hydrogels, and methods of preparation and uses of the same. The hydrogels may be gelled at room temperature, in the absence of added light or heat, to yield ultra-strong hydrogel fibers suitable for load-bearing applications, or as adhesives or coatings. The hydrogels may include a polymerized polymer containing acrylic acid, additional acrylic acid, an organic acid such as citric acid, and an oxidizing agent such as a persulfate salt. Silver-lignin nanoparticle suspensions may be used to initiate a free radical oxidative decarboxylation reaction in the disclosed compositions. Hydrogels may be prepared from such compositions through incubation leading to gelling. The gelled hydrogels may be stretched or spun into hydrogel fibers having desirable mechanical properties, such as strength, stretchability, and adhesion.
C08L 33/26 - Homopolymers or copolymers of acrylamide or methacrylamide
A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
Described herein, is an isolated cell comprising a recombinant T cell receptor (TCR) and a TCR-pathway-dependent reporter, wherein the recombinant T cell receptor is specific for a disease-relevant antigen bound to an MHC molecule. Also described are methods of use for the isolated cell as an assay to determine the function or potency of a peptide-major histocompatibility complex (pMHC) coupled to a nanoparticle (pMHC-NP) that can be used as a medicine for treating an autoimmune disease or cancer.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Disclosed is a method for treatment of a subject having, or suspected of having, a cancer, in particular colorectal cancer, using an immune checkpoint inhibitor in combination with one or more bacteria selected from Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species, wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody or an anti-PD-1 antibody, wherein antibiotic therapy may precede the use of the immune checkpoint inhibitor and the one or more bacteria.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/708 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (Switzerland)
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV) (Switzerland)
UTI LIMITED PARTNERSHIP (Canada)
Inventor
Courtine, Grègoire
Bloch, Jocelyne
Squair, Jordan
Phillips, Aaron
Mahe, Loïs
Abstract
The present invention relates to a neuromodulation/neurostimulation system (10) for stimulating at least one neuronal circuitry responsible for micturition control in a mammal with bladder disfunction, especially for bladder relaxation and/or for bladder voiding, said system (10) comprising: - at least one control unit (12), and - at least one stimulation unit (14), configured and arranged to provide electrical stimulation to the spinal cord of said mammal. Further, the present invention relates to the use of the neuromodulation/neurostimulation system (10).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are glycoprotein NMB (GPNMB)-binding chimeric antigen receptors (CARs). In some embodiments, a CAR of the present disclosure comprises an extracellular GPNMB-binding domain (e.g., a single chain antibody, such as an scFv), a transmembrane domain, and one or more intracellular signaling domains. Nucleic acids and expression constructs encoding such CARs are also provided. Also provided are cells (e.g., immune cells, such as T cells) comprising the nucleic acids and expression constructs. Aspects of the present disclosure further include compositions comprising a population of such cells expressing the GPNMB-binding CAR on their surface, as well as methods of administering such compositions to treat a condition associated with GPNMB expression and/or activity in a subject in need thereof. Non-limiting examples of conditions associated with GPNMB expression and/or activity include cancer (e.g., sarcomas, such as soft tissue sarcomas), neurodegenerative diseases, and the like.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/62 - DNA sequences coding for fusion proteins
85.
MICROGELS, METHODS, COMPOSITIONS, AND USES THEREOF
A hybrid microgel, comprising a thermoresponsive polymer, and a polysaccharide comprising amorphous domains, the thermoresponsive polymer being grafted to the polysaccharide; methods of making the hybrid microgel, and compositions useful for tissue engineering comprising the hybrid microgel.
C08L 51/02 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers grafted on to polysaccharides
C08J 3/02 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
C09K 8/588 - Compositions for enhanced recovery methods for obtaining hydrocarbons, i.e. for improving the mobility of the oil, e.g. displacing fluids characterised by the use of specific polymers
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
86.
Transitional tapping atomic force microscopy for high-resolution imaging
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
88.
ELECTRODES USEFUL FOR MEMBRANE-FREE ELECTRODE ASSEMBLIES, MEMBRANE-FREE ELECTRODE ASSEMBLIES, METHODS, AND USES THEREOF
Electrodes useful for membrane- free electrode assemblies, membrane-free electrode assemblies, methods of making, and uses thereof. The electrodes comprise a catalyst layer; and a solid polymer electrolyte layer for ion-conduction deposited on the catalyst layer. The solid polymer electrolyte layer is deposited on a catalyst layer as an ionomer resin solution and forms an ion conducting layer thereby eliminating the need for a stand-alone membrane that is introduced as a separate component into electrode assemblies.
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
Institute of Geology and Geophysics, Chinese Academy of Sciences (China)
UTI LIMITED PARTNERSHIP (Canada)
Inventor
Cao, Changqian
Bryant, Steven L.
Abstract
Polymer-coated nanoparticles, a composite nano-emulsion and a macro-emulsion are provided. In the polymer-coated nanoparticles, the polymer self-assembles into a cage-shaped structure to coat the nanoparticles; and the nanoparticles are iron-containing metal oxides. The polymer-coated nanoparticle shell provided by the present invention can be used as a stabilizer to prepare a composite nano-emulsion, and furthermore, a stable macro-emulsion can be prepared at an extremely low concentration. The problems that high-concentration surfactants and solid particles are required to stay on an oil-water interface in macro-emulsion synthesis, and surface tension is reduced to stabilize large oil drops are overcome.
C08K 9/08 - Ingredients agglomerated by treatment with a binding agent
C08J 3/03 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
90.
Compositions and methods of use for treatment or improvement of the condition and appearance of skin
Compositions, formulations and methods of use thereof for treating, preventing and improving the condition and aesthetic appearance of skin are described. Compositions, formulations and methods of use thereof for treatment of dermis wounds, aged dermis, diseased dermis or damaged dermis are also described. The present compositions and formulations comprise a peptide with an amino acid sequence of QHREDGS (SEQ ID NO: 1) and methods of use thereof.
4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
92.
SYSTEM AND METHOD FOR PROCESSING FIBER-REINFORCED COMPOSITES IN ADDITIVE MANUFACTURING
A method is provided for producing a fiber-reinforced composite in a fused filament fabrication (FFF) process for additive manufacturing, including: depositing, using a deposition tool, a composite raster by extruding the fiber-reinforced composite onto a deposition surface; miming a consolidation tool having a heated or heat-inducing non-rolling tip over the deposited composite raster, to apply a shear force to reduce fiber waviness; and applying, using the consolidation tool, heat and a compressive force concurrent with the application of the shear force to pressurize the composite raster and reduce void content. The process reduces porosity while at the same time, increasing fiber straightness in composite material deposited via FFF, increasing reinforcement-matrix adhesion, and matrix cohesion. A separate, independently controlled tool runs over previously deposited material using an interior point-out technique. The method reduces void contents of high fiber volume composites to a level suitable for the production of structural composite parts for aerospace applications, without requiring post-consolidation operations.
B29C 64/194 - Processes of additive manufacturing involving additional operations performed on the added layers, e.g. smoothing, grinding or thickness control during lay-up
B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
C02F 1/46 - Treatment of water, waste water, or sewage by electrochemical methods
C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
94.
FILM FOR DEICING AND ELECTROMAGNETIC INTERFERENCE SHIELDING APPLICATIONS
The present disclosure generally relates to a method of producing a film for use with de-icing and EMI shielding. The film is a multilayer film on a substrate comprising a layer of PEFOT:PSS, a AgNW layer and a second PEDOT:PSS layer. The film is produced by a simple low-cost fabrication method and does not require vacuum, pressing or high temperature processing.
B32B 37/24 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the properties of the layers with at least one layer not being coherent before laminating, e.g. made up from granular material sprinkled onto a substrate
H05B 3/84 - Heating arrangements specially adapted for transparent or reflecting areas, e.g. for demisting or de-icing windows, mirrors or vehicle windshields
B32B 15/02 - Layered products essentially comprising metal in a form other than a sheet, e.g. wire, particles
95.
METHODS OF CHANGING ION CONCENTRATIONS IN SURFACE WATER, AND SYSTEMS THEREOF
C02F 1/46 - Treatment of water, waste water, or sewage by electrochemical methods
C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
G01D 5/00 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable
G01L 9/00 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by electric or magnetic pressure-sensitive elementsTransmitting or indicating the displacement of mechanical pressure-sensitive elements, used to measure the steady or quasi-steady pressure of a fluid or fluent solid material, by electric or magnetic means
G01M 15/14 - Testing gas-turbine engines or jet-propulsion engines
G12B 1/00 - Sensitive elements capable of producing movement or displacement for purposes not limited to measurementAssociated transmission mechanisms therefor
Methods are disclosed for dispersing nanoparticles in solvents, involving the use of a cationic species and an anionic species, where at least one of the ionic species is soluble in the nonpolar solvent and the other ionic species has a relatively strong affinity for the surface of the nanoparticles. The cationic species and the anionic species together form a cluster of ion pairs shielding the nanoparticles and enhancing their dispersibility in the nonpolar solvent.
The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells using biocompatible bioabsorbable nanospheres. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
100.
SYSTEMS AND METHODS FOR PREDICTING CARDIOTOXICITY OF MOLECULAR PARAMETERS OF A COMPOUND BASED ON MACHINE LEARNING ALGORITHMS
Systems and methods are provided for predicting cardiotoxicity of molecular parameters of a compound. A computer can provide as input to a machine learning algorithm the molecular parameters of the compound. The molecular parameters can include at least structural information about the compound. The machine learning algorithm can have been trained using respective molecular parameters of compounds known to have cardiotoxicity and of compounds known not to have cardiotoxicity. The computer can receive as output from the machine learning algorithm a representation of the predicted cardiotoxicity of each molecular parameter of at least a subset of the molecular parameters of the compound.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
G16B 35/00 - ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
